Tokyo, Japan and Cambridge, Massachusetts, USA | November 19, 2026
Eisai Co., Ltd. and Biogen Inc. have announced new clinical research findings from the Clarity AD cerebrospinal fluid (CSF) substudy, evaluating the effects of lecanemab (LEQEMBI®) in patients with early Alzheimer’s disease (AD) who also exhibit alpha-synuclein (α-Syn) co-pathology. The findings were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2026, held in Boston and online. The analysis provides additional insights into how co-existing protein abnormalities may influence disease progression and treatment outcomes in Alzheimer’s disease. Lecanemab demonstrated a reduction in clinical decline compared with placebo at 18 months, including among participants who tested positive for α-Syn pathology. The findings highlight the importance of understanding multiple disease-related biological pathways when evaluating treatments for neurodegenerative disorders.
CSF Analysis Identifies Alpha-Synuclein Co-Pathology in Alzheimer’s Patients
The Clarity AD CSF substudy investigated the prevalence of alpha-synuclein pathology among individuals with early Alzheimer’s disease and examined its relationship with amyloid-beta (Aβ) accumulation and clinical disease progression. Researchers evaluated 623 cerebrospinal fluid samples collected during screening or baseline assessments using the Amprion SYNTap seed amplification assay (SAA), a specialized laboratory technique designed to detect abnormally structured α-Syn protein aggregates. Among the amyloid-beta-positive participants who were randomized to receive lecanemab or placebo and had available α-Syn testing results, 400 participants were included in the main analysis. The findings showed that α-Syn pathology was more prevalent among amyloid-beta-positive individuals than among amyloid-beta-negative individuals, with prevalence rates of 20.4% and 10.0%, respectively. The difference was statistically significant (p=0.001). Researchers also observed that participants with α-Syn-positive results had a higher baseline amyloid burden, averaging 86 Centiloids compared with 67 Centiloids in participants who tested negative. These findings suggest that α-Syn co-pathology may contribute to differences in disease characteristics and clinical progression among individuals with Alzheimer’s disease.
Lecanemab Demonstrates Clinical Benefit in α-Syn-Positive Patients
An important finding from the analysis was that lecanemab demonstrated a reduction in clinical decline compared with placebo at Month 18, both in the overall α-Syn-tested population and in participants who tested positive for α-Syn pathology. The exploratory post hoc analysis included 82 α-Syn-positive participants and evaluated treatment outcomes using established Alzheimer’s disease assessment measures. Based on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), the reduction in clinical decline compared with placebo was 41% in the α-Syn-positive subgroup, compared with 27% in the overall Clarity AD population and 26% in the α-Syn-tested population. Additional assessments showed reductions of 43% in the α-Syn-positive subgroup using the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 14 (ADAS-Cog14), compared with 26% in the overall Clarity AD population. Similarly, the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale (ADCS MCI-ADL) showed a 43% reduction in the α-Syn-positive subgroup compared with 37% in the overall study population. These results suggest that lecanemab may provide clinical benefit even when alpha-synuclein co-pathology is present. However, the subgroup analysis was exploratory and post hoc, and the findings should not be interpreted as definitive evidence of greater treatment efficacy in α-Syn-positive patients.
Eisai and Biogen Advance Alzheimer’s Disease Research
The findings strengthen the ongoing research efforts of Eisai and Biogen in developing treatments targeting the underlying biological mechanisms of Alzheimer’s disease. Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to target aggregated soluble and insoluble forms of amyloid-beta, particularly protofibrils believed to contribute to neuronal damage and cognitive decline. The treatment is approved in multiple countries for eligible patients with early Alzheimer’s disease. Eisai leads global clinical development and regulatory submissions for lecanemab, while both companies collaborate on its commercialization and promotion. The research presented at CTAD 2026 also emphasizes the importance of investigating co-existing protein pathologies, including amyloid-beta, tau and alpha-synuclein, to better understand the biological complexity of neurodegenerative diseases. By combining clinical assessments with advanced CSF biomarker testing, researchers can gain additional insights into disease progression and potential treatment responses. The latest Clarity AD findings provide further evidence supporting continued investigation of amyloid-targeting therapies in patients with complex Alzheimer’s disease pathology, while highlighting the need for additional research to establish the clinical significance of different co-pathology profiles.
Source: Eisai Co., Ltd. and Biogen Inc press release



